Jomrich, Gerd
Kollmann, Dagmar
Wilfing, Lavinia
Radosavljevic, Sanja
Ramazanova, Dariga
Ristl, Robin
Grose, Richard P.
Ilhan-Mutlu, Aysegül
Preusser, Matthias
Fassnacht, Christina
Tsai, Yi-Chien
Guenova, Emmanuella
Schoppmann, Sebastian F.
Funding for this research was provided by:
Promedica Stiftung (1406/M, 1412/M)
Krebsforschung Schweiz (KFS-4243-08-2017)
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (PMPDP3_151326)
the Clinical Research Priority Program (CRPP) of the University of Zurich, and the European Academy of Dermatology and Venereology (PPRC-2019-20)
Medical University of Vienna
Article History
Received: 2 March 2021
Accepted: 4 March 2021
First Online: 5 May 2021
Conflict of interest
: This study was partially supported by the Promedica Stiftung (1406/M and 1412/M), the Swiss Cancer Research Foundation (KFS-4243-08-2017), the Swiss National Science Foundation (PMPDP3_151326), the Clinical Research Priority Program (CRPP) of the University of Zurich, and the European Academy of Dermatology and Venereology (PPRC-2019-20). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. A. Ilhan-Mutlu participated in advisory boards from MSD, BMS, and Servier; received lecture honoraria from Eli Lilly, MSD, and Servier; is the local PI for clinical trials sponsored by BMS and Roche; and received travel support from BMS, Roche, and Servier. M. Preusser has received honoraria for lectures, consultation, or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, BMJ Journals, MedMedia, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dome, Tocagen, Adastra. G. Jomrich, D. Kollmann, L. Wilfing, S. Radosavljevic, D. Ramazanova, R. Ristl, R.P. Grose, C. Fassnacht, Y.-C. Tsai, E. Guenova, and S.F. Schoppmann declare that they have no competing interests.